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Introduction 
Ovarian adenocarcinoma is the fifth 
leading cause of death for women in the 
United States, with an estimated 15,520 
deaths per year.1 However, ovarian 
adenocarcinoma presenting as axillary 
lymphadenopathy is quite a rare occurrence.  
This case documents an ovarian 
adenocarcinoma presenting as axillary 
lymphadenopathy, with a focus on the 
importance of the surgeon differentiating the 
axillary mass from metastatic breast cancer. 
 
Case Report 
A 74-year-old female was referred for 
the evaluation of right axillary 
lymphadenopathy detected on a routine 
mammogram. She denied fever, fatigue, 
recent travel, axillary pain, or skin changes. 
Her age of menarche was 15, her first 
pregnancy was at the age of 23, and her age 
of menopause was 43.  Her family history 
was significant for two sisters with breast 
cancer, one of whom was diagnosed in her 
forties and died within two years. Her other 
sister was diagnosed in her seventies and 
still living at that time.  She also had 
multiple paternal aunts and cousins 
diagnosed with breast cancer. There was no 
family history of ovarian cancer.   
The patient’s past medical history 
included hypertension, ulcers, hyper-
lipidemia, diverticulosis, hemorrhoids, and a 
myocardial   infarction.    Her   past  surgical  
 
history included removal of two benign 
growths from her left breast at the age of 28.  
Her last mammogram and breast exam 
performed one year previously were normal.  
The physical exam at presentation 
revealed right axillary adenopathy with no 
observable primary mass. There was no 
erythema, pain with palpation, or swelling. 
Ultrasound of the axilla easily identified the 
enlarged nodes and was used to perform fine 
needle aspiration (FNA). FNA of the node 
revealed adenocarcinoma of undefined 
origin. A breast MRI did not reveal a 
primary mass. CT of the chest and a bone 
scan also were negative.   
CT of the abdomen and pelvis revealed 
multiple lobulated peritoneal and omental 
masses, as well as intraabdominal masses in 
the region of the gall bladder and spleen, 
including a 16 X 41 mm mass in the right 
lower quadrant. Additionally, a complex 
cystic lesion was seen in the left adnexa.  A 
core biopsy of right axillary lymph nodes, 
CA-125 level, and staining for estrogen, 
progesterone, HER2, Ki-67, and CA-125 
were performed. Her CA-125 level was 
elevated to 900 ng/ml and the axillary core 
biopsy stained positive for CA-125 within 
the neoplastic cells.  The positivity rate of 
the estrogen receptor was 1%, progesterone 
90%, and HER2 2+, features which can be 
seen with ovarian or breast carcinoma. Ki-
67 positivity was 90%, indicating a high 
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proliferative rate. The high CA-125 level 
along with the CT findings indicated 
metastatic ovarian cancer as the diagnosis. 
A port-a-catheter was placed and the 
patient was started on six cycles of 
chemotherapy with paclitaxel and 
carboplatin. After completing her 
chemotherapy regimen, a diagnostic 
bilateral mammogram revealed improved 
right axillary adenopathy, while a sonogram 
of the right breast showed no abnormal 
lymphadenopathy. Her CA-125 levels 
normalized.  At last follow-up, a CT of the 
abdomen and pelvis revealed no increase in 
number or size of nodes.  The main post 
treatment side effect was grade three 
neuropathy. 
 
 
Figure 1.  CT scan showing left ovarian 
mass. 
 
 
Figure 2. CT scan showing peritoneal 
metastases. 
Discussion 
Most ovarian cancers are epithelial in 
origin and result from malignant 
transformation of the ovarian epithelium, 
which is contiguous with the peritoneum.2 
At the time of staging, approximately 85% 
of ovarian cancer remains confined to the 
peritoneal cavity.  Distant metastases at the 
time of presentation occurred in 8% of 
patients in one study and were most 
common in the liver, pleura, and lung.3  
Ovarian cancer presenting as axillary 
lymphadenopathy is quite rare.  The largest 
study to date on the topic of ovarian cancer 
presenting as extra-abdominal lymph-
adenopathy involved a twenty-year review 
of cases.4  In this twenty-year period, 35 
extra-abdominal lymphadenopathic present-
ations of ovarian, fallopian tube, or 
peritoneal carcinoma were found. Only two 
cases of peritoneal disease presented as 
axillary lymphadenopathy. A case 
presentation similar to that described here 
was reported in 1997 after a patient was 
erroneously treated for metastatic breast 
cancer.5  
Breast cancer is a logical consideration 
in a patient with axillary lymphadenopathy, 
but alternative diagnoses must be 
entertained. Skin infections, cat-scratch 
disease, tularemia, sporotrichiosis, sarcoid-
osis, syphilis, leprosy, brucellosis, 
melanoma, lymphoma and Kaposi’s 
sarcoma can result in axillary lympha-
denopathy.6,7 Key aspects of the history 
include the presence of constitutional 
symptoms, recent travel, or high risk 
behaviors. Careful examination of other 
nodal sites also is required.   
This patient’s history of breast surgery 
for the removal of tumors coupled with a 
fine needle aspiration of adenocarcinoma 
suggested breast cancer, but the imaging 
studies, an MRI and CT, revealed no 
obvious site of a primary breast cancer. 
Breast MRI is highly sensitive in the 
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detection of occult breast cancer in patients 
with axillary lymphadenopathy.8 Evidence 
of abdominal and adnexal masses are more 
convincing of a primary ovarian neoplasm.  
The CA-125 level at presentation was 
900 ng/ml and supported the diagnosis of 
metastatic ovarian adenocarcinoma.  
Although elevated CA-125 levels can be 
associated with other benign and malignant 
conditions, at levels above 320 ng/ml, there 
is a higher sensitivity and specificity for 
ovarian cancer (71% sensitivity, 84% 
specificity).9 Additionally, above levels of 
510 ng/ml, there is increased sensitivity and 
specificity for peritoneal implants outside of 
the pelvis as well as lymph node metastasis 
(67% sensitive, 80% specific).  
Although a biopsy of the ovarian mass is 
usually required for complete confirmation 
of ovarian cancer, it was not performed in 
this case. The chemotherapy regimen would 
not have been altered by this diagnosis and 
the patient was already responding to 
chemotherapy. In addition, the patient’s age 
and cardiac history raised concerns that she 
may not tolerate such a large operation.  The 
CT image of an adnexal mass, a CA-125 
level of 900 ng/ml, as well as the axillary 
node staining positive with CA-125, was 
sufficient for a diagnosis of primary ovarian 
cancer with axillary metastasis. The 
decrease of the CA-125 level to within 
normal limits after treatment with paclitaxel 
and carboplatin supported the diagnosis.    
Axillary lymphadenopathy as an initial 
presentation of ovarian cancer is quite rare. 
Based on previous reports, our patient was 
the only one that did not receive surgical 
resection, only chemotherapy, and at last 
follow-up was performing well.  For breast 
surgeons and referring providers, axillary 
lymphadenopathy in a female of older age, 
especially in the absence of an obvious 
breast lesion, potentially could represent 
metastasis from primary ovarian carcinoma. 
Recognition of this differential diagnosis 
could prevent unnecessary lumpectomy or 
mastectomy and lead to better outcomes 
with the appropriate treatment of the true 
primary cancer. 
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